Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

AVENIR & CONSEILS - PHARMAFINANCE : revenue, balance sheet and financial ratios

AVENIR & CONSEILS - PHARMAFINANCE is a French company founded 15 years ago, specialized in the sector Conseil pour les affaires et autres conseils de gestion. Based in LORIENT (56100), this company of category PME shows in 2024 a net income positive of 395 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - AVENIR & CONSEILS - PHARMAFINANCE (SIREN 522627157)
Indicator 2024 2021
Revenue N/C N/C
Net income 395 196 € 312 392 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2024, AVENIR & CONSEILS - PHARMAFINANCE generates positive net income of 395 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2021-2024: 312 k€ -> 395 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

395 196 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 6%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 93%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

5.878%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

93.206%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

30.4%

Solvency indicators evolution
AVENIR & CONSEILS - PHARMAFINANCE

Sector positioning

Debt ratio
5.88 2024
2021
2024
Q1: 0.0
Med: 4.0
Q3: 41.75
Average +10 pts over 2 years

In 2024, the debt ratio of AVENIR & CONSEILS - PHARM... (5.88) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
93.21% 2024
2021
2024
Q1: 4.27%
Med: 38.89%
Q3: 76.46%
Excellent

In 2024, the financial autonomy of AVENIR & CONSEILS - PHARM... (93.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 4370.27. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

4370.273

Liquidity indicators evolution
AVENIR & CONSEILS - PHARMAFINANCE

Sector positioning

Liquidity ratio
4370.27 2024
2021
2024
Q1: 138.89
Med: 313.79
Q3: 966.61
Excellent

In 2024, the liquidity ratio of AVENIR & CONSEILS - PHARM... (4370.27) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Positioning of AVENIR & CONSEILS - PHARMAFINANCE in its sector

Comparison with sector Conseil pour les affaires et autres conseils de gestion

Valuation estimate

Based on 69 transactions of similar company sales in 2024, the value of AVENIR & CONSEILS - PHARMAFINANCE is estimated at 2 736 932 € (range 1 033 406€ - 6 851 318€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
69 tx
1033k€ 2736k€ 6851k€
2 736 932 € Range: 1 033 406€ - 6 851 318€
NAF 5 année 2024

Valuation method used

Net Income Multiple
395 196 € × 6.9x = 2 736 933 €
Range: 1 033 406€ - 6 851 318€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 69 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Conseil pour les affaires et autres conseils de gestion)

Compare AVENIR & CONSEILS - PHARMAFINANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Conseil pour les affaires et autres conseils de gestion

Frequently asked questions about AVENIR & CONSEILS - PHARMAFINANCE

What is the revenue of AVENIR & CONSEILS - PHARMAFINANCE ?

The revenue of AVENIR & CONSEILS - PHARMAFINANCE is not publicly disclosed (confidential accounts filed with INPI).

Is AVENIR & CONSEILS - PHARMAFINANCE profitable?

Yes, AVENIR & CONSEILS - PHARMAFINANCE generated a net profit of 395 k€ in 2024.

Where is the headquarters of AVENIR & CONSEILS - PHARMAFINANCE ?

The headquarters of AVENIR & CONSEILS - PHARMAFINANCE is located in LORIENT (56100), in the department Morbihan.

Where to find the tax return of AVENIR & CONSEILS - PHARMAFINANCE ?

The tax return of AVENIR & CONSEILS - PHARMAFINANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does AVENIR & CONSEILS - PHARMAFINANCE operate?

AVENIR & CONSEILS - PHARMAFINANCE operates in the sector Conseil pour les affaires et autres conseils de gestion (NAF code 70.22Z). See the 'Sector positioning' section above to compare the company with its competitors.